Biopharma’s relationship with AI is reaching a tipping point. While Big Pharma doubles down on AI to streamline development, a wave of startups is betting the tech can overhaul R&D from the ground up. But can AI really crack the sector’s biggest challenges — from ballooning budgets to years-long approval timelines?

This year, we’re bringing that debate center stage — virtually in the morning and in-person that evening with exclusive, live editorial sessions and a Networking Reception in New York City. Joined by top industry leaders and led by award-winning Senior Biopharma Correspondent Andrew Dunn, AI Day will dig into the science, strategy and real-world implications of AI’s growing footprint in drug development.